Background: The purpose of this article is to critically review the data accumulated to date from studies evaluating the hemodynamic and clinical effects of right ventricular apical pacing during ...

THE question of how well the compensated human heart with a fixed rate in the physiologic range is capable of adapting to the demands for increased cardiac output has very practical implications for ...

January 27, 2006-- Patients with conventional right ventricular pacemakers who develop severe heart failure may benefit from an upgrade to a biventricular pacing (BVP) system. The results of the small ...

A 67-year-old man with acute anterolateral myocardial infarction had recurrent ventricular fibrillation that required insertion of temporary pacemaker. When a permanent pacemaker was inserted stable ...

Estimates suggest that around three million Americans are living with cardiac pacemakers, according to the American Heart Association. Now, thanks to MountainStar Healthcare, a new kind of pacemaker – ...

Results from SORIN GROUP’s long-term clinical randomized trial showed that the SafeR pacing mode significantly reduces heart failure events (death and hospitalization) Nice, France, – Sorin Group, a ...

Reduced cardiac efficiency caused by suboptimal synchronization of the heart's normal contraction might contribute to the development of or exacerbate heart failure. Conceptually and in practice ...

The cardiac pacemaker harmlessly dissolves over the course of 35 days. (Courtesy: Northwestern University) Temporary cardiac pacemakers provide essential pacing for patients with short-term heart ...

Heart problems are nothing new. Humans have been fascinated by electrocardiography since the era of Hippocrates (via St. Luke's Hospital Cardiology Department). With each passing century, medicine's ...

This story is part of a series on the current progression in Regenerative Medicine. This piece discusses the regeneration of the cardiovascular system. In 1999, I defined regenerative medicine as the ...

The prospective multi-centre BIO-LivIQ trial will enrol 325 patients across 60 sites worldwide.